ALX Oncology Inc.

0.60
0.02 (3.45%)
At close: Apr 24, 2025, 3:59 PM
0.58
-3.84%
After-hours: Apr 24, 2025, 06:54 PM EDT
3.45%
Bid 0.58
Market Cap 32.21M
Revenue (ttm) n/a
Net Income (ttm) -134.85M
EPS (ttm) -2.58
PE Ratio (ttm) -0.23
Forward PE -0.41
Analyst Buy
Ask 0.62
Volume 332,509
Avg. Volume (20D) 864,714
Open 0.61
Previous Close 0.58
Day's Range 0.58 - 0.63
52-Week Range 0.46 - 17.82
Beta 1.20

About ALXO

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell c...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 17, 2020
Employees 80
Stock Exchange NASDAQ
Ticker Symbol ALXO
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for ALXO stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 397.18% from the latest price.

Stock Forecasts
1 month ago
-19.08%
ALX Oncology Holdings shares are trading lower. Th... Unlock content with Pro Subscription
1 month ago
+25.96%
ALX Oncology Holdings shares are trading higher after Piper Sandler and Jefferies upgraded their respective price targets on the stock.